NEW YORK — PixCell Medical said on Wednesday that it has signed a distribution agreement for its HemoScreen hematology analyzer in the United Arab Emirates with MakGroup Healthcare.
HemoScreen is a US Food and Drug Administration-cleared and CE-marked five-part differential complete blood count analyzer for point-of-care use. It provides results from a fingerstick blood sample within five minutes and does not require specially trained lab technicians to operate, PixCell said.
Under the terms of the deal, Dubai-based MakGroup will exclusively distribute the analyzer in the UAE. Additional terms were not disclosed.
In mid-2021, PixCell inked a distribution deal for HemoScreen in Israel with Gamidor Diagnostics. Last month, the Israeli firm struck a distribution pact for the instrument in the UK and Ireland with Katalyst Diagnostics.